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Plasma membranes from rat mammary gland containing a high concentration of PH]oxytocin binding sites (2.8 pmol/mg 
protein) were used for photoaffinity labehing experiments. Competitive binding experiments how that these receptors 
bind with high aflinity the specific oxytocin agonist [Thr*, Sar7]oxytocin and the analogue of I-deamino-[8-lysinelvaso- 
pressin containing a photoreactive azidobenzoyl group (Abz) at the side chain of lysine. The tritium-labelled (50 Ci/mol) 
photoreactive analogue incorporated into a membrane protein with an apparent relative molecular mass of 65000 &- 
3000 Da (n = 16). The labelling of this protein was completely suppressed by an excess of oxytocin. 
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1. INTRODUCTION 
The neurohypophysial nonapeptide oxytocin 
stimulates the contraction of mammary 
myoepithelial cells. Previous studies have shown 
the existence of specific oxygen receptors which 
bind oxytocin with high affinity (Kn l-5 nM) 
[1,2]. A good correlation between the ability of 
analogues to inhibit [3H]oxytocin binding to these 
receptors and their milk ejecting potencies has 
been demonstrated [2]. 
The number of receptors in the rat mammary 
gland increases about lOO-fold from the first day 
of pregnancy to late lactation [3]. Mammary mem- 
branes containing a high concentration of oxytocin 
receptors have been used to study the molecular 
properties of oxytocin receptors. Gel filtration 
analysis of the detergent solubilized membranes in- 
dicated that the solubilized [‘Hloxytocin-binding 
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component was present in multiple molecular mass 
forms [4]: molecular mass values ranged from 
about 40 to ~200 kDa. To determine the func- 
tional size of the oxytocin receptor in rat mam- 
mary gland membranes, radiation inactivation of 
[‘Hloxytocin binding sites was employed [51. By 
this method the molecular mass of the mammary 
receptor was estimated to be 57.5 f 3.8 kDa. For 
further studies and for the isolation of the mam- 
mary oxytocin receptor, identification of the 
receptor protein would be helpful. In this study we 
used photoaffinity labelling of the membrane 
bound mammary oxytocin receptor and SDS gel 
analysis to identify the oxytocin receptor protein 
and to determine its apparent molecular mass. 
2. MATERIALS AND METHODS 
2.1. Materials 
The photoreactive ligand [3H][Mpa1,Lys(Abz)8]vasopressin 
was prepared by reaction of [Mpa’,Lyss]vasopressin with suc- 
cinimidyl 4azidobenzoate (50 Ci/mmol, NEN) as described 
161. [‘HlOxvtocin (20 Ci/mmol) and [Arg] [‘Hlvasopressin 
(f3H]AVP) (18 Ci/mmol) were from Amersham. The oxytocin 
analogue [Thr“,Sar’]oxytocin was obtained from Dr Z. 
Grzonka (University of Gdansk, Poland). 
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2.2. Preparation of mammary membrane fractions 3rA 
Rat mammary membranes were prepared from involuted 
mammary tissue after weaning as described [4] and stored 
frozen at -80°C. 
2.3. Receptor binding assays 
Mammary gland membranes (80-1OOrg protein) were in- 
cubated with [“H]OT or with [3H]AVP at 30°C. The binding 
assay and the analysis of data were performed as has been 
described for experiments with myometrial membranes [7]. 
2.4. Photoaffinity [abelling experiments 
Plasma membranes (1 mg) from rat mammary gland contain- 
ing 2.8 pmol [‘H]OT-binding sites/mg protein were incubated 
at 30°C for 30 min with 7 nM [‘H][Mpa’,Lys(Abz)*]vaso- 
pressin in 350 ~1 binding buffer (50 mM Hepes, pH 7.6, 10 mM 
MnCl2). After dilution with 3 ml ice-cold binding buffer con- 
taining 5 mM p-aminophenyl-alanine as scavenger, the mixture 
was exposed in a quartz tube to three 1 ms flashes produced in 
an apparatus for high energy ultraviolet irradiation [8]. After ir- 
radiation, plasma membranes were collected by centrifugation 
at 20000 x g for 30 min and the photolabelling was repeated 
with additional ligand following the same protocol. The 
photolabelled membrane proteins were separated by SDS gel 
electrophoresis and the radioactivity was determined as describ- 
ed [7]. 
3. RESULTS 
Fig.1 shows the dose dependent specific binding 
of [3H]oxytocin to a plasma membrane prepara- 
tion from rat mammary gland. The data were 
analyzed by curve fitting procedures (fig.lA) and 
by Scatchard analysis (fig.lB). The apparent 
dissociation constant KD for [3H]oxytocin binding 
was calculated to be 4.9 + 0.2 nM (n = 3), the max- 
imal binding capacity Bmax was estimated to be 
2.8 pmol/mg membrane protein. The maximal 
binding capacity of these membranes for 
[Arg*] [3H]vasopressin was roughly the same as for 
[3H]oxytocin. The receptor affinity for vasopressin 
was about 5fold lower as compared to oxytocin; 
the KD for [3H]vasopressin binding was calculated 
to be 26 + 2 nM (n = 3). 
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Fig.1. Binding of [3H]oxytocin to mammary membranes. 
Membranes (80-1OOyg per test) were incubated at 30°C for 
30 min with various concentrations of [‘HJOT. Nonspecific 
binding was determined in the presence of a lOO-fold excess of 
oxytocin and was subtracted from the total binding. Each point 
represents the mean of three experimental values. The binding 
curve was fitted as described in section 2 (A) and the data were 
also analysed and represented as Scatchard plot (B). 
The ligand specificity of the oxytocin binding 
site was examined (fig.2). The specific oxytocin 
agonist [Thr4,Sar7]oxytocin exhibits a high selec- 
tivity for oxytocin-like relative to vasopressin-like 
activities [9]; furthermore, its activity in the rat 
milk ejection assay is higher (731 + 57 U/mg) than 
that of oxytocin (486 + 15 U/mg). This analogue 
was more potent in displacing [3H]oxytocin from 
its binding site in mammary membranes than 
unlabelled oxytocin (fig.2). In competition ex- 
periments with [3H]AVP and unlabelled peptides, 
oxytocin and [Thr4,Sar7]oxytocin were more po- 
tent in displacing [3H]AVP from membranes than 
unlabelled vasopressin (fig.3). [Thr4,Sar7]oxytocin 
(1 PM) displaced [3H]AVP neither from the renal 
V2 nor from the hepatic VI receptor [7]. These 
results indicate that membranes from rat mam- 
mary gland contain high affinity oxytocin recep- 
tors which bind with lower affinity vasopressin. 
The photoreactive analogue of l-deamino- 
[Lys’lvasopressin containing an azidobenzoyl 
(Abz) group at the side chain of lysine, 
[Mpa’,Lys(Abz)‘]vasopressin, retains a high af- 
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Fig.2. Competitive binding of [‘Hloxytocin and different 
peptides to mammary membranes. Plasma membranes 
(30-100/g) were equilibrated at 30°C with a fixed 
concentration of [‘HJOT (10 nM) and varying concentrations 
of nonlabelled peptides for 30 min. The reduction in binding of 
[‘H]OT produced in two identical experiments by various 
concentrations of unlabelled peptides is shown. BO is specific 
binding of [‘H]OT in the absence of competing ligand and B is 
specific binding of [‘H]OT in the presence of competing ligand. 
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Fig.3. Competitive binding of [‘H]AVP, AVP and 
[Th?,Sar’]OT to mammary membranes. Membranes were 
equilibrated with [‘H]AVP (10 nm). Other experimental 
conditions as described for fig.2. 
finity for the oxytocin receptor in mammary mem- 
branes. We found a higher affinity in competition 
experiments with [3H]oxytocin of this analogue 
than of either vasopressin or oxytocin (fig.2). 
In photoaffinity labelling experiments the 
photoreactive ligand with tritium incorporated in 
the benzene ring of the azidobenzoyl group 
(50 Ci/mmol) was used [6]. Membranes were in- 
cubated with the photoreactive ligand at concen- 
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Fig.4. Effect of oxytocin on photoaffinity labelling. Mammary 
membranes were incubated with 7 nM photoreactive ‘H- 
labelled ligand in the absence of oxytocin and in the presence 
of 3.5 pM oxytocin (0). After incubation the suspension was 
diluted and the ligand photoactivated. This procedure was 
repeated and the membrane proteins separated on gradient SDS 
gels. 
trations of 4-7 nM (3-5 times the KD value of the 
ligand). To increase the specificity of the labelling, 
the concentration of the free ligand was reduced 
after incubation by dilution. Gel electrophoretic 
analysis (fig.4) showed the preferential abelling of 
a membrane protein with an apparent M, of 
65000 f 3000 (n = 16). The labelling of this pro- 
tein was completely suppressed by a 500-fold ex- 
cess of oxytocin. In most experiments a second 
protein with a molecular mass of 28000 f 2000 
(n = 11) was labelled by the ligand with lower yield 
as compared to the 65 kDa protein. 
4. DISCUSSION 
The oxytocin receptor on membranes from 
mammary gland retains a high affinity for an 
analogue of vasopressin, containing a photoreac- 
tive group at the side chain of Lys’. The amino 
acid in position 8 of the oxytocin sequence is the 
hydrophobic leucine residue. Apparently, the in- 
troduction of a hydrophobic aryl azido group in 
the side chain of the Lys* residue increases the af- 
finity of the resulting analogue as compared to 
vasopressin for the oxytocin binding site. The 
photoaffinity labelling experiments provide 
335 
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evidence for an oxytocin receptor protein with an 
apparent M, of 65000 + 3000. The labelling of this 
protein was completely inhibited by an excess of 
oxytocin. The labelled protein with an A4, of 
roughly 28000 could either be a cleavage product 
of the oxytocin receptor protein or it could be 
associated with the receptor. One has to take into 
account the experimental errors in the A4 values 
for the mammary oxytocin receptor determined by 
SDS-gel electrophoretic analysis (MI = 65000 + 
3000) and by radiation inactivation (M = 57 500 + 
3800). The results from photoaffinity labelling and 
radiation inactivation provide evidence that a pro- 
tein with an M, between 58000 and 65000 
represents a functional mammary oxytocin recep- 
tor. Purification of the receptor and reconstitution 
studies will be necessary to support this con- 
clusion. 
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